8-K: Citius Pharma Reports First Revenue, Faces Nasdaq Delisting Risk

Citius Pharmaceuticals, Inc. announced its first revenue of $3.9 million from LYMPHIR sales but received a Nasdaq delisting notice for its common stock trading below $1.00 per share.

Summary

• Citius Pharmaceuticals, Inc. reported its first revenue of $3.9 million from initial sales of LYMPHIR in December 2025.
• The company received a Nasdaq notice on February 9, 2026, indicating non-compliance with the minimum $1.00 bid price rule for continued listing.
• Citius Pharmaceuticals has 180 calendar days, until August 10, 2026, to regain compliance with Nasdaq's Bid Price Rule.
• Cash and cash equivalents totaled $7.7 million as of December 31, 2025.
• Net proceeds of approximately $20.9 million were generated from equity financings during the fiscal first quarter 2026.
• The net loss applicable to common stockholders was $8.2 million, or $(0.41) per share, an improvement from a net loss of $9.8 million, or $(1.30) per share, in the prior-year period.
• Research and development expenses decreased to $1.6 million from $2.1 million in the prior-year period.
• General and administrative expenses increased to $5.7 million from $5.4 million in the prior-year period.
• Stock-based compensation expense increased to $4.3 million from $2.5 million in the prior-year period.
• LYMPHIR (denileukin diftitox-cxdl) was successfully launched in the U.S. in December 2025 for adult patients with relapsed or refractory Stage II-III cutaneous T-cell lymphoma (CTCL).
• Citius Pharma owns approximately 74.8% of Citius Oncology, Inc.
• Management estimates the initial market for LYMPHIR currently exceeds $400 million and is growing.
• The late-stage pipeline includes Mino-Lok, which met primary and secondary endpoints in its Phase 3 trial, and Halo-Lido, which completed its Phase 2b trial in 2023.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a mixed filing. The successful launch of LYMPHIR and initial revenue generation are significant positive milestones, but these are heavily counterbalanced by the Nasdaq delisting notice, which introduces substantial uncertainty and risk regarding the company's market presence and future financing capabilities.

Positives

• Achieved commercial inflection with $3.9 million in first reported revenue from LYMPHIR sales in December 2025.
• Successfully launched LYMPHIR in the U.S. for adult patients with relapsed or refractory Stage II-III CTCL.
• Reported early physician adoption and nationwide product availability for LYMPHIR.
• Deployed an AI-enabled commercial platform to support targeted physician engagement and efficient market penetration for LYMPHIR.
• Advancing international patient access for LYMPHIR through negotiated agreements with regional partners in Europe and the Middle East.
• Received encouraging early signals from investigator-initiated Phase I combination studies evaluating LYMPHIR for expanded clinical utility in recurrent solid tumors and CAR-T lymphodepletion regimens.
• Mino-Lok met primary and secondary endpoints in its pivotal Phase 3 trial.
• Net loss applicable to common stockholders decreased to $8.2 million from $9.8 million year-over-year.
• Net loss per share improved to $(0.41) from $(1.30) year-over-year.
• Cash and cash equivalents increased to $7.7 million as of December 31, 2025, from $4.25 million at September 30, 2025.

Negatives

• Received a Nasdaq delisting notice on February 9, 2026, due to the common stock bid price closing below the minimum $1.00 per share requirement for 30 consecutive business days.
• Must regain compliance with Nasdaq's Bid Price Rule by August 10, 2026, or face potential delisting.
• Reported a significant net loss of $8.2 million for the fiscal first quarter 2026.
• General and administrative expenses increased to $5.7 million from $5.4 million in the prior-year period.
• Stock-based compensation expense increased to $4.3 million from $2.5 million in the prior-year period.
• The company's forward-looking statements highlight a need for substantial additional funds to fund operations for at least the next 12 months as a going concern.

Risks

• Ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream.
• The estimated markets for LYMPHIR and product candidates and their acceptance by any market.
• Ability to secure strategic partnerships and expand international access to LYMPHIR.
• Ability to use the latest technology to support commercialization efforts for LYMPHIR.
• Physician and patient acceptance of LYMPHIR in a competitive treatment landscape.
• The ability of LYMPHIR and product candidates to impact the quality of life of target patient populations.
• Need for substantial additional funds and ability to raise additional money to fund operations for at least the next 12 months as a going concern.
• Ability to maintain Nasdaq's continued listing standards, specifically the Bid Price Rule.
• Reliance on third-party logistics providers, distributors, and specialty pharmacies to support commercial operations.
• Ability to educate providers and payers, secure adequate reimbursement, and maintain uninterrupted product supply.
• Post-marketing requirements and ongoing regulatory compliance related to LYMPHIR.
• Risks relating to the results of research and development activities, including those from any new pipeline assets.
• Ability to procure cGMP commercial-scale supply.
• Ability to obtain, perform under, and maintain financing and strategic agreements and relationships.
• Market and other conditions.
• Risks related to growth strategy.
• Patent and intellectual property matters.
• Government regulation.
• Impact of any future public health risks.

Future Outlook

The company expects momentum for LYMPHIR sales to build as it deploys its full commercial organization and technology-driven platform to expand patient access and drive market penetration. It sees multiple avenues for growth, including encouraging early signals from investigator-initiated studies, opportunities to expand access in international markets, and the potential to build a durable oncology franchise. The company remains committed to financial stewardship and advancing its late-stage pipeline, which includes Mino-Lok and Halo-Lido.

Management Comments

• "I am thrilled to report that we have successfully transitioned to a revenue generating company following Citius Oncology’s December 2025 launch of LYMPHIR." Leonard Mazur, Chairman and Chief Executive Officer of Citius Oncology and Citius Pharma.
• "While we are still in the early stages of the launch, we expect momentum to build as we continue to stand up the full commercial organization and more fully deploy our technology-driven platform to expand patient access and drive market penetration." Leonard Mazur.
• "Looking ahead, we see multiple avenues for growth, including encouraging early signals from investigator-initiated studies, opportunities to expand access in international markets, and the potential to build a durable oncology franchise." Leonard Mazur.
• "Most importantly, LYMPHIR now offers patients living with cutaneous T-cell lymphoma a meaningful new treatment option and a more hopeful future." Leonard Mazur.
• "We remain committed to financial stewardship to sustain this momentum, and focused execution to advance our late-stage pipeline, which includes Mino-Lok and Halo-Lido. Our goal remains to serve our community with first-in-class critical care products, and in so doing maximize long-term shareholder value." Leonard Mazur.

Industry Context

StockSavvy.ai notes that the successful launch of LYMPHIR and the generation of initial revenue mark a significant transition for Citius Pharmaceuticals into a commercial-stage biopharmaceutical company, a critical step for many development-stage firms. The focus on rare oncology markets like CTCL, estimated at over $400 million and underserved, aligns with a broader industry trend of targeting niche indications with high unmet needs and potentially higher pricing power. However, the Nasdaq delisting notice highlights the ongoing challenge for smaller biotechs to maintain market capitalization and share price stability, even with positive clinical and commercial developments.

Comparison to Industry Standards

• The initial revenue of $3.9 million from LYMPHIR in its first month of launch is a positive indicator for a rare disease drug, though it's too early to compare directly to established blockbusters like Bristol Myers Squibb's Opdivo or Merck's Keytruda, which generate billions annually across broader oncology indications.
• The market size estimate for LYMPHIR in CTCL exceeding $400 million suggests a significant opportunity within its niche, comparable to other orphan drugs that have achieved multi-hundred-million dollar annual sales, such as Alexion's Soliris for rare blood disorders.
• The Nasdaq delisting warning for falling below $1.00 per share is a common challenge for smaller biopharmaceutical companies, particularly those in development stages or early commercialization, where market sentiment can be volatile. Many emerging biotechs, unlike large-cap pharmaceutical companies such as Pfizer or Johnson & Johnson, frequently face such listing compliance issues.

Stakeholder Impact

• Shareholders: Potential for increased value from LYMPHIR revenue and pipeline progress, but significant risk of delisting from Nasdaq could severely impact liquidity and share price. Equity financings during the quarter diluted existing shareholders.
• Patients (CTCL): LYMPHIR offers a meaningful new treatment option and a more hopeful future.
• Employees: Continued focus on commercial organization build-out and pipeline advancement suggests ongoing employment stability and growth opportunities.
• Creditors: The company's ability to raise capital and generate revenue will be crucial for its financial health and ability to meet obligations.

Next Steps

• Continue to stand up the full commercial organization for LYMPHIR.
• More fully deploy the technology-driven platform to expand patient access and drive market penetration for LYMPHIR.
• Pursue opportunities to expand access for LYMPHIR in international markets.
• Advance late-stage pipeline products, Mino-Lok and Halo-Lido, engaging with the FDA for next steps.
• Evaluate options for regaining compliance with Nasdaq's Bid Price Rule by August 10, 2026.

Key Dates

Recommendation

The initial revenue from LYMPHIR is a crucial positive step, demonstrating successful commercialization and validating the company's transition. However, the immediate threat of Nasdaq delisting due to the sub-$1.00 share price introduces substantial uncertainty and risk. While the company has a compliance period, the outcome is not assured. Investors should hold to monitor the company's progress in regaining Nasdaq compliance and the sales trajectory of LYMPHIR, as these factors will dictate future valuation. The long-term potential is present, but the near-term listing risk warrants caution.

Keywords

Citius Pharmaceuticals, CTXR, LYMPHIR, Nasdaq delisting, biopharmaceutical, oncology, CTCL, Mino-Lok, Halo-Lido, revenue, financial results, biotech, pharmaceuticals, drug launch, critical care